The European Medicines Agency has begun reviewing new EU marketing authorization applications (MAAs) for two drugs it had previously rejected – Alsitek (masitinib) and quizartinib – and a product that was approved but then withdrawn for commercial reasons – catumaxomab.
Alsitek, from AB Science, and quizartinib, from Daiichi Sankyo, are for treating amyotrophic lateral sclerosis (ALS) and acute...








